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Purpose—Triple-negative breast cancer (TNBC) requires the identification of reliable predictors 
of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the 
performance of the TNBCtype-4 classifier in a cohort of TNBC patients treated with neoadjuvant 
carboplatin and docetaxel (TCb).
Methods—TNBC patients were accrued in a non-randomized trial of neoadjuvant carboplatin 
AUC 6 and docetaxel 75 mg/m2 for 6 cycles. Response was evaluated in terms of pathological 
complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans et al. Lehmann's 
subtyping was performed using the TNBCtype online tool from RNAseq data, and germline 
sequencing of a panel of 7 DNA damage repair genes was conducted.
Results—94 out of the 121 patients enrolled in the trial had RNAseq available. The overall pCR 
rate was 44.7%. Lehmann subtype distribution was: 34.0% BL1, 20.2% BL2, 23.4% M, 14.9% 
LAR and 7.4% were classified as ER+. Response to NACT with TCb was significantly associated 
with Lehmann subtype (p=0.027), even in multivariate analysis including tumor size and nodal 
involvement, with BL1 patients achieving the highest pCR rate (65.6%), followed by BL2 
(47.4%), M (36.4%) and LAR (21.4%). BL1 was associated with a significant younger age at 
diagnosis and higher ki67 values. Among our 10 germline mutation carriers, 30% were BL1, 40% 
were BL2 and 30% were M.
Conclusions—TNBCtype-4 is associated with a significantly different pCR rates for the 
different subtypes, with BL1 and LAR displaying the best and worse responses to NACT 
respectively.
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INTRODUCTION
Triple-negative breast cancer (TNBC), defined by the lack of expression of estrogen receptor 
(ER), progesterone receptor (PR) and HER-2 overexpression, represents approximately 15% 
of breast cancers, has no targeted therapies available yet and is associated with an 
unfavorable prognosis. Many patients with early stage TNBC are now treated with 
neoadjuvant chemotherapy (NACT), as pre-surgery treatment enables a higher rate of breast 
conserving surgery, an early exposure of micrometastatic disease to systemic therapy, and, 
mainly, an in vivo test of the tumor sensitivity to chemotherapy. In addition, it has been 
consistently shown that pathological response to NACT is strongly correlated with prognosis 
in TNBC. Patients obtaining a pathological complete response (pCR, defined as non-
invasive residual disease in breast and lymph nodes) have a high likelihood of cure, while 
those with significant residual disease have a dismal prognosis (1,2).
The addition of platinum salts to standard anthracycline-taxane neoadjuvant regimens has 
demonstrated a significant increase in pCR rates in TNBC, reaching above 50% (3,4), 
although at the expense of significantly higher toxicity. For instance, the combination of 
carboplatin and weekly paclitaxel, followed by dose-dense doxorubicin and 
cyclophosphamide, reached pCR rates of 54% (ypT0/is ypN0) in the CALGB40603 trial, 
while the combination without carboplatin achieved a pCR rate of 41% (3). In a similar 
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manner, neoadjuvant treatment with paclitaxel, non-pegylated liposomal doxorubicin and 
bevacizumab, with or without carboplatin, achieved pCR rates of 53.2% and 36.9%, 
respectively (p=0.005). In contrast, classical regimens based on anthracyclines and taxanes 
have shown pCR rates of around 35–40% (5). Neoadjuvant regimens based on taxanes and 
platinum salts, without anthracyclines, such as the combination of docetaxel and carboplatin, 
reach pCR rates of around 50% (6,7). However, comparison among different studies could 
be biased by different patient population and stage of disease.
Nevertheless, about half of the patients will not achieve a pCR, and a significant proportion 
of these patients will relapse despite NACT. Thus, TNBC requires a reliable predictor of 
response to NACT that will enable the selection of patients for whom conventional 
chemotherapy is insufficient, and direct them to clinical trials with new drugs or new 
therapeutic approaches.
Intrinsic subtype by gene expression profiling provided a new insight into breast cancer, 
classifying these tumors into 4 subtypes (8,9). Although TNBC and basal-like were initially 
considered equivalent, TNBC is in fact a highly heterogeneous disease, and only 70–80% of 
TNBC are classified as PAM50 basal-like subtype (10). Other gene expression-based 
classifiers of TNBC have arisen in recent years, with some sharing features and subtypes 
between them, but without complete overlap (11,12). The Lehmann classification 
(TNBCtype) has become one of the most studied (13). Initially composed of 6 subtypes, 
further analysis revealed that the mesenchymal stem-like (MSL) and immunomodulatory 
(IM) subtypes were more a reflection of the tumor microenvironment rather than of the own 
tumor cells, and, therefore, the classification was simplified into 4 TNBC subtypes: basal-
like 1 (BL1), basal-like 2 (BL2), mesenchymal (M) and luminal androgen receptor (LAR) 
(13). A correlation of Lehmann subtypes with pathological response to NACT based on 
anthracyclines and taxanes was previously observed with the BL1 group having the highest 
pCR rate (15). The presence of a subset of TNBC tumors that bear features of ER-positive 
breast cancer has been known for long, with an overexpression of hormone-regulated 
pathways, and in special androgen signaling (16,17). There is signs of antitumor activity 
with androgen blockade in patients with expression of androgen receptor in IHC staining 
and predictive signatures of androgen blockade efficacy are being developed (18,19). In the 
gene expression level, all new TNBC classifications have identified this LAR subtype, that 
corresponds with PAM50 non-basal tumors (11–15).
In this study, we aimed to evaluate the predictive value of Lehmann subtyping in a TNBC 
cohort treated with neoadjuvant carboplatin and docetaxel. In addition, we analyzed its 
correlation with the PAM50 intrinsic subtype classification.
PATIENTS AND METHODS
Patients and treatment
An ad-hoc study of predictive biomarkers was conducted within a prospective, non-
randomized trial evaluating the clinical efficacy of neoadjuvant carboplatin and docetaxel 
previously published. Patients with newly diagnosed TNBC were accrued from 7 institutions 
across Spain and Peru. Eligibility criteria included a pathologically confirmed diagnosis of 
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invasive breast cancer, age over 18, stage I to III disease and no prior chemotherapy 
treatment for any malignancies. TNBC was defined as the absence of expression of estrogen 
and progesterone receptor (ER and PR < 1%) and HER2 status was defined as negative 
using the ASCO/CAP guidelines (20,21). IHC for ER, PR and Ki67 was determined by local 
review. Patients received six cycles of carboplatin AUC 6 and docetaxel 75 mg/m2 every 3 
weeks followed by surgery. G-CSF support was used following individual institution 
guidelines. Postoperative radiotherapy was indicated following clinical practice guidelines 
and adjuvant treatment in case of residual disease was left at the physician discretion.
The study was registered at clinicaltrials.gov (NCT 01560663) and was approved by the 
Ethical Board at all the participating institutions. All patients signed a written informed 
consent.
Assessment of response
Pathological complete response was defined as the absence of invasive tumor in the breast 
and axillary lymph nodes (ypT0/is ypN0) and residual disease was assessed by Symmans 
residual cancer burden calculator (22). Assessment of response was done by local pathology.
Genomic profiling
Extraction of nucleic acids was done centrally at the Translational Oncology Laboratory 
(LAOT) at the Hospital Gregorio Marañon (Madrid, Spain).
RNA was extracted from formalin fixed paraffin-embedded (FFPE) core biopsies prior to 
treatment initiation from the breast tumor, using the RNasy FFPE (Quiagen, Germany). 
RNA quantification and quality control were performed on NanoDrop 2000. Paired samples 
from non-responders are not available yet.
Intrinsic subtype was performed from PAM110 panels, including the PAM50 gene set, on 
the nCounter platform (NanoString Technologies Inc, Seattle, USA) at the LAOT facilities. 
The PAM110 assay included the 50 PAM50 genes plus an additional set aimed to identify 
the claudin-low signature and neoangiogenesis signatures (see list of genes in 
Supplementary Table 2). Further details can be found at http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GPL17071. RNA sequencing (RNAseq) was performed at the University 
of North Carolina at Chapel Hill (NC, USA). Total FFPE RNA was used to create a total 
RNAseq library using the Illumina TruSeq Total RNA library Prep Kit with Ribo-Zero Gold 
Kit. Libraries were then sequenced two per lane on a HiSeq2500 with a 48x7x48 bp 
configuration. Alignment with the Human Genome Sequence GRCh37 was done using 
MapSplice v 2.2.1 and RSEM v1.3.0. Analysis of RNAseq data was done in collaboration 
between the University of North Carolina and the Hospital Gregorio Marañon.
RSEM normalized data was uploaded into the TNBCtype online tool: http://
cbc.mc.vanderbilt.edu/tnbc in order to get Lehmann's subtype distribution (23,24). Patients 
were classified into four subtypes: BL1 (basal-like 1), BL2 (basal-like 2), M (mesenchymal) 
and LAR (luminal androgen receptor).
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In addition, germline DNA from the patients was extracted from whole blood samples prior 
to the initiation of therapy using the QIAamp the DNA Blood Midi kit (Quiagen, Germany). 
A panel of 7 DNA damage repair genes (BRCA1, BRCA2, BARD1, PALB2, RAD50, 
RAD51C and RAD51D) were analyzed through targeted next-generation sequencing, by 
Sistemas Genómicos (Valencia, Spain).
Statistical analysis
All statistical analyses were performed on R v3.2.1. Fisher’s exact test and Chi square test 
were used for the comparison of categorical variables, Student’s t test and Kruskal-Wallis 
test were used for independent continuous variables, and mutivariate analyses were 
performed with multiple logistic regressions. Confidence intervals for categorical variables 
have been estimated with the Clopper-Pearson method.
RESULTS
Patients
From 2010 to 2015, 121 TNBC patients were accrued in seven participating institutions in 
Spain and Peru. RNAseq could be performed in 97 of the patients included in the cohort 
(80.2%). In the remaining patients, insufficient amount of RNA extracted from the core 
biopsies precluded an appropriate analysis. In addition, 2 patients were lost to follow-up 
with no available information about their outcomes and another patient received only 1 cycle 
of TCb due to toxicity, and was considered as not evaluable for the analysis. Figure 1.
Baseline characteristics of the patients are summarized in table 1. Median age at diagnosis 
was 51 years. There were no significant differences between global trial population and 
patients included in the molecular analysis both in baseline characteristics and response rates 
(table 1). Almost two thirds of the patients had axillary involvement, 52.1% and 46.8% of 
the patients had stage II and III disease, respectively. pCR rate among the 94 available 
patients for molecular analysis was 44.7% and up to 56.4% achieved a pathological good 
response (pCR or RCBI). Median follow-up was 35 months.
Lehmann subtype distribution
Lehmann subtype distribution was as follows: 34.0% BL1, 20.2% BL2, 23.4% M and 14.9% 
LAR. Seven patients (7.4%) in our cohort were classified as ER-positive with Lehmann 
subtyping tool and were discarded for the subtype distribution. Table 2.
In this cohort, 83% were considered Basal-like by PAM50 subtype, approximately two 
thirds were classified as BL1 and BL2 by TNBCtype-4 (64.1%) and most of the remaining 
corresponded to M subtype (28.2%). On the contrary, only 6.2% of our non-basal patients by 
PAM50 were classified as BL1 or BL2, while most of these patients corresponded to LAR 
(68.8%).
Of the 7 patients considered ER-positive with regards to ESR1 expression, 42.9% were 
basal-like by PAM50, 42.9% normal-like and 14.3% HER2E.
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Baseline characteristics according to Lehmann subtype
We compared baseline characteristics among each of the Lehmann subtypes. Table 3. Except 
for age and ki67, no significant differences in the clinical-pathological features were found 
between the 4 subtypes. BL1 and LAR were associated with a significant younger and 
higher age at diagnosis, respectively (median age 41 and 67.5 years), p<0.01. Patients with 
LAR tumors included in our cohort tended to have more locally advanced tumors than the 
rest of the subtypes. Indeed, BL1 and LAR tumors had a trend towards a more frequent 
nodal involvement (78.1% and 85.7% vs 52.6% and 57.1% for BL2 and M, respectively) 
although these differences did not reach statistical significance (p=0.18). Significant 
differences in ki67 values were observed across subtypes (p<0.01), BL1 tumors displayed 
the highest ki67 values and LAR the lowest. There were no differences in the percentage of 
high grade tumors (grade 3) nor in tumor size.
Response according to Lehmann subtype
Response to NACT with TCb was significantly associated with Lehmann subtype (p=0.027). 
BL1 patients achieved the highest pCR rate (65.6%, 95% confidence interval (CI) 46.8–
81.4%), followed by BL2 (47.4%, 95% CI 24.4–71.1%), M (36.4%, 95% CI 17.2–59.3%) 
and LAR (21.4%, 4.7–50.8%). Figure 2. Patients classified as ER-positive obtained a pCR 
rate of 14.3% (95% CI 0.4–57.9%).
When compared to BL1, LAR and M subtypes had significant lower pCR rates, with an OR 
of achieving a pCR of 0.14 (95% CI 0.32–0.64) and 0.30 (95% CI 0.09–0.95) respectively 
(p<0.01 and p=0.037). This significant association was maintained when multivariate 
analysis including tumor size and nodal involvement were performed for both M and LAR 
subtypes (p=0.015 and p=0.008), and BL2 showed a trend towards a worse response too 
(p=0.075).
In accordance with these results, RCB considered as a continuous variable, was significantly 
different among all four subtypes (p=0.004).
Lehmann subtypes among BRCA/non BRCA carriers
Mutational profiling of homologous repair genes was available for 85 of our patients 
(90.4%). Among our 10 germline mutation carriers (8 in BRCA1, 1 in BRCA2 and 1 in 
BARD), 30% (n=3) were BL1, 40% (n=4) were BL2 and 30% (n=3) were M. pCR rates 
among BRCA carriers were similar to those obtained in the general TNBC population 
(66.6% (n=2) for BL1, 50% (n=2) for BL2 and 33.3% (n=1) for M; p=1.00). Supplementary 
table 1.
DISCUSSION
In this study we evaluated the distribution of TNBCtype-4 subtypes according to the 
classification of Lehmann et al and its association with response to NACT based on 
carboplatin and docetaxel (14).
The TNBCtype distribution in our cohort is very similar to the one described by Lehmann et 
al with their last modified classification (14). BL1 was the most frequent subtype, and the 
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combination of BL1 and BL2 reached around 50–55% of the samples in both their cohort 
and ours. Most of the data available on TNBC subtype classification and response to 
neoadjuvant chemotherapy is based on the former Lehmann’s classification into 6 different 
subtypes (13). For instance, according to the original classification, genomic profiling of 350 
TNBC revealed that 15% and 6% were BL1 and BL2, 20% IM, 8% LAR, 17% M and 7% 
MSL (25). Similar distribution was observed in TNBC included in the GEICAM/2006-03 
trial (26). It is worth noting that up to 7% of our TNBC patients were classified as ER+ with 
regards to ESR1 gene expression, with no specific correlation with PAM50 intrinsic subtype. 
Prat et al had 17% of their patients classified as ER+, with a similar PAM50 distribution 
among this group than in our cohort (25).
Regarding the distribution of the TNBCtype in PAM50 basal versus non-basal TNBC, we 
found a distinct distribution pattern between both groups. PAM50 basal-like were enriched 
in basal subtypes, whereas LAR was the main component of the non-basal tumors, in 
accordance to previously described data (25,27).
We found a significant association of the TNBCtype-4 classification with pCR following 
neoadjuvant carboplatin and docetaxel (p=0.027), with BL1 displaying the highest pCR rates 
(65.6%). Although differential response with TNBCtype has shown inconsistent results 
across different cohorts of patients, the benefit in terms of pCR for BL1 has been invariably 
described (25). It is noteworthy that our BL1 patients exhibited higher pCR rates than those 
described previously (65.6% vs 40–55% with different combinations) (13,23). BL1, in 
addition, seems to display the best disease free-survival at 10 years, with a global DFS of 
60% (14).
While the TNBCtype classification seems to bring homogeneous data with regards to pCR 
and long-term outcome for BL1, LAR and BL2 subtypes harbor contradictory data across 
different studies for long-term survival and pCR rates respectively, although no formal 
analyses have been conducted. For instance, initial data suggested that BL2 tumors might be 
a group with a special chemoresistance, as described by Masuda et al, who found no pCR 
within this group of patients, in a cohort of patients treated with anthracyclines and taxanes 
(15). However, our BL2 patients achieved a pCR rate of 47.4%, the second highest rate 
among our cohort. This finding is supported by other studies that found pCR rates among 
BL2 of around 35–40% (26). As for LAR tumors, while they have been invariably 
associated with low response rate to NACT, data regarding long-term survival has been 
contradictory, displaying the best and worst outcome in different studies (14,15,27).
This study may shed some light to the tailoring strategies of neoadjuvant treatments in 
TNBC, since we could hypothesize that the use of TCb might enable the omission of 
anthracyclines in specific subsets of TNBC patients. In fact, since BL1 subtype is associated 
with a significantly younger age at diagnosis and the best pCR rate and 10 year-DFS, this 
subset of patients could presumably be spared from the anthracycline long-term cardiac 
toxicity. In addition, the CREATE-X trial recently demonstrated a significant increase in 
DFS (3y-DFS rate: 69.8% vs 56.1%, HR=0.58, 95% CI 0.39–0.87) and OS (3y-OS rate: 
78.8%vs 70.3%, HR=0.52, 95% CI 0.30–0.90) among TNBC with residual disease after 
NACT who received adjuvant capecitabine (29). We can speculate that capecitabine should 
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be tested earlier on in association with other drugs in TNBCtype-4 patients not likely to 
achieve a pCR, such as LAR and M. Thus, performing this classification and tailoring 
NACT among TNBC patients would definitely improve cost-effectiveness in this setting and 
optimize treatment, preventing unnecessary toxicities.
On the other hand, LAR tumors have consistently shown low response rates and pCR in 
other series (30), and, however inconsistent across studies, AR TNBC seem to show a better 
long-term prognosis, supporting that TNBC/LAR tumors have a distinct biology compared 
to non-LAR TNBC (15,30–32). AR-driven TNBC represent a subset of tumors for which 
pCR might not be prognostic, and thus, that may display a favorable outcome despite 
residual disease after NACT (33,34). This chemoresistance of AR-driven TNBC could be 
filled by molecularly targeted therapies directed against the androgen receptor (13), which 
have been evaluated both in the metastatic and early setting (18). For instance, several trials 
are evaluating adjuvant enzalutamide in TNBC patients with AR+ disease (NCT02750358), 
as well as in the neoadjuvant setting in combination with chemotherapy (NCT02689427). 
Although adjuvant antiandrogen therapy in patients with residual disease following NACT 
seemed like an interesting option to consider, the phase III ENDEAR trial (NCT02929576) 
was prematurely discontinued.
In addition to the use of the former TNBCtype classification in most of the published data, 
there is little evidence regarding TNBCtype performance in patients treated with non-
anthracycline, platinum salt-containing regimens. Table 4. A recent phase 2 study evaluating 
the addition of neoadjuvant everolimus to cisplatin and paclitaxel, performed TNBCtype in 
48 of their patients, exhibiting similar trends of response to our cohort overall, although it 
included the MSL subtype (28).
We then analyzed the TNBCtype and PAM50 distribution among carriers of mutation in a 
panel of 7 homologous repair genes, with all our tumors classified as basal-like by PAM50 
and as BL1, BL2 and M with TNBCtype-4. We also analyzed response with regards to 
mutational status, with no differences in pathological response between carriers and non-
carriers. Data regarding TNBCtype distribution among BRCA carriers is still scarce. Isakoff 
et al described 7 metastatic TNBC with BRCA mutation, and found 42.9% of BL1, 28.6% of 
M and 14.3% of MSL and unstable respectively (35). Moreover, Telli at al found 9.1% of 
BL1, 36.4% of IM, 18.2% M, 9.1% MSL and 27.3% of unstable among 11 BRCA1/2 
carriers within the PrECOG0105 trial (36). Nevertheless, all these data should be taken with 
caution due to the small sample size of all three studies.
Our study has some notable strengths. First, it is one of the first cohorts presenting data with 
the new classification TNBCtype-4. Second, most of the published data comes from 
retrospective analysis of patients heterogeneously treated, mainly with combinations of 
anthracyclines and taxanes. Our cohort, in contrast, is uniformly treated with carboplatin and 
docetaxel, and no data has been published yet about TNBCtype performance in response 
prediction with this regimen. Third, we present novel data on the subtype distribution and 
response among BRCA-related genes mutation carriers.
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However, our study has some significant limitations, such as the short follow-up available to 
date, that precludes survival analysis and, mainly, the small sample size and thus, the wide 
confidence interval ranges obtained.
In conclusion, although confirmation by other independent series is required, Lehmann’s 
refined classification TNBCtype-4 could help select the neoadjuvant therapy in TNBC. 
Patients with BL subtypes could be candidates for standard chemotherapy, while the 
remaining subtypes may need to be directed for new, experimental therapies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Although gene expression profiling has provided a better understanding of TNBC, there 
still is a need for the identification of predictors of response to chemotherapy in this 
subset of patients. Our study brings innovative data on the predictive value of Lehmann’s 
refined classification tool (TNBCtype-4) in a homogeneous cohort of patients treated 
with a platinum-containing, anthracycline-free, neoadjuvant regimen, carboplatin and 
docetaxel. This study shows a meaningful differential response to neoadjuvant 
chemotherapy among the different subtypes, with BL1 and LAR displaying the highest 
and lowest pCR rates, respectively (65.6% vs 21.4%). This robust association, together 
with the novel data on the subtype distribution within BRCA-mutated TNBC, provides a 
new evidence of TNBC heterogeneous biology, which may enable a future selection of 
therapies in these patients.
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Figure 2. Symmans RCB according to Lehmann subtype
RCB: residual cancer burden. pCR: pathological complete response. BL1: basal-like 1. BL2: 
basal-like 2. M: mesenchymal. LAR: luminal androgen receptor.
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Table 1
Baseline characteristics of our cohort
CI: Confidence interval. MRI: magnetic resonance imaging. N+: node-positive, N0: node-negative. NA: not 
available. T stage: tumor stage according to AJCC 7th edition. AJCC: American Joint Committee on Cancer. 
G: grade. Fisher’s exact test has been used for categorical variables, Mann Whitney test for comparison of 2 
means (age, tumor size and ki67). * Hispanic definition refers to individuals from Latin American ancestry.
N=121 N=94 p
Age
Median (range) 51.4 (28–80) 51 (28–78) 0.61
Ethnicity*
Caucasian 117 (96.7%) 90 (95.7%) 1.0
Asian 2 (1.7%) 2 (2.1%)
Hispanic 2 (1.7%) 2 (2.1%)
Menstrual status at diagnosis
Premenopausal 58 (47.9%) 43 (45.7%) 0.51
Perimenopausal 1 (0.8%) 1 (1.1%)
Postmenopausal 60 (51.2%) 49 (52.1%)
NA 2 (1.7%) 1 (1.1%)
Tumor size by MRI (mm)
Median, range 40 (9–180) 42 (12–180) 0.65
Axillary involvement
N0 43 (35.5%) 29 (30.9%) 0.07
N+ 78 (64.5%) 65 (69.1%)
T stage
T1 4 (3.3%) 4 (4.3%) 0.71
T2 66 (54.5%) 49 (52.1%)
T3 24 (19.8%) 20 (21.3%)
T4 27 (22.3%) 21 (22.3%)
AJCC TNM
I 1 (0.8%) 1 (1.1%) 0.52
II 66 (54.5%) 49 (52.1%)
III 54 (44.6%) 44 (46.8%)
Ki67
Median, range 70% (3–100%) 70% (3–100%) 0.95
<50% 38 (31.4%) 35 (37.2%)
Histological grade
G1–2 31 (25.6%) 22 (23.2%) 0.35
G3 87 (71.9%) 70 (74.5%)
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N=121 N=94 p
NA 3 (2.5%) 2 (2.1%)
Response data
pCR 57 (47.1%) 42 (44.7%) 0.38
RD 64 (52.9%) 52 (55.3%)














































































































































































































































































































































































































































































Echavarria et al. Page 19
Table 4
pCR rates according to Lehmann TNBCtype-4
Cb: carboplatin. T: docetaxel. CDDP: cisplatin. N: number of patients.
NCT 01560663 Lehmann 2016(13) Jovanovic 2017 (24)
N 94 306 48
Treatment TCb x 6 Anthracyclines and taxanes combinations CDDP-Paclitaxel +/− Everolimus
TNBCtype-4
BL1 32 (34.0%) 110 (35.9%) 15 (31%)
BL2 19 (20.2%) 67 (21.9%) 3 (6%)
M 22 (23.4%) 77 (25.2%) 15 (31%)




BL1 21 (65.6%) 46 (41.8%) 8 (53%)
BL2 9 (47.4%) 12 (17.9%) 1 (33%)
M 8 (36.4%) 29 (37.7%) 7 (47%)
LAR 3 (21.4%) 15 (28.8%) 1 (25%)
ER+ 1 (14.3%) -- --
MSL -- -- 3 (33%)
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